{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T19:40:42Z","timestamp":1775590842071,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.009","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:38Z","timestamp":1749770138000},"page":"439-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in the Management of Prostate Cancer"],"prefix":"10.1016","volume":"35","author":[{"given":"V\u00e9rane","family":"Achard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan Dal","family":"Pra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0001","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2004.0022","article-title":"Biochemical relapse after primary treatment for prostate cancer: studies on natural history and therapeutic considerations","volume":"2","author":"Rosenbaum","year":"2004","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0002","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.ijrobp.2012.05.023","article-title":"Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer","volume":"85","author":"Spratt","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"17","key":"10.1016\/j.semradonc.2025.04.009_bib0003","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.281.17.1591","article-title":"Natural history of progression after PSA elevation following radical prostatectomy","volume":"281","author":"Pound","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.009_bib0004","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","article-title":"Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy","volume":"294","author":"Freedland","year":"2005","journal-title":"Jama"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0005","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0006","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk Stratification of Patients with Recurrence After Primary Treatment for Prostate Cancer: A Systematic Review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.009_bib0007","unstructured":"EAU guidelines prostate cancer. Accessed March 1, 2025. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/treatment."},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0008","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External Validation of the European Association of Urology Biochemical Recurrence Risk Groups to Predict Metastasis and Mortality After Radical Prostatectomy in a European Cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0009","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.eururo.2019.07.001","article-title":"Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension","volume":"76","author":"Hackman","year":"2019","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.009_bib0010","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"issue":"9858","key":"10.1016\/j.semradonc.2025.04.009_bib0011","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0012","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"issue":"26","key":"10.1016\/j.semradonc.2025.04.009_bib0013","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0014","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified Versus Conventional-dose Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy: The SAKK 09\/10 Randomized Phase 3 Trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.eururo.2019.05.011","article-title":"Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy","volume":"76","author":"Akthar","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0016","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.euf.2020.11.002","article-title":"Europa Uomo Patient Reported Outcome Study (EUPROMS): Descriptive Statistics of a Prostate Cancer Survey from Patients for Patients","volume":"7","author":"Venderbos","year":"2021","journal-title":"Eur Urol Focus"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0017","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euf.2023.05.006","article-title":"The Europa Uomo Patient Reported Outcome Study 2.0-Prostate Cancer Patient-reported Outcomes to Support Treatment Decision-making","volume":"9","author":"Venderbos","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"10260","key":"10.1016\/j.semradonc.2025.04.009_bib0018","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.009_bib0019","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.009_bib0020","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.semradonc.2025.04.009_bib0021","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.semradonc.2025.04.009_bib0022","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.semradonc.2025.04.009_bib0023","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1001\/jama.299.23.2760","article-title":"Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy","volume":"299","author":"Trock","year":"2008","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0024","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030740","article-title":"Salvage Radiotherapy versus Observation for Biochemical Recurrence following Radical Prostatectomy for Prostate Cancer: A Matched Pair Analysis","volume":"14","author":"Tilki","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.semradonc.2025.04.009_bib0025","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","article-title":"Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy","volume":"25","author":"Stephenson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.semradonc.2025.04.009_bib0026","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy","volume":"34","author":"Tendulkar","year":"2016","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.semradonc.2025.04.009_bib0027","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-Specific Antigen Level at the Time of Salvage Therapy After Radical Prostatectomy for Prostate Cancer and the Risk of Death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0028","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0029","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.009_bib0030","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10338","key":"10.1016\/j.semradonc.2025.04.009_bib0031","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"10442","key":"10.1016\/j.semradonc.2025.04.009_bib0032","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"10442","key":"10.1016\/j.semradonc.2025.04.009_bib0033","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/S0140-6736(24)00549-X","article-title":"Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0034","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.eururo.2024.07.026","article-title":"Randomised Trial of No, Short-term, or Long-term Androgen Deprivation Therapy with Postoperative Radiotherapy After Radical Prostatectomy: Results from the Three-way Comparison of RADICALS-HD (NCT00541047)","volume":"86","author":"Parker","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.009_bib0035","doi-asserted-by":"crossref","first-page":"S1428","DOI":"10.1016\/j.annonc.2022.08.067","article-title":"LBA64 Duration of androgen suppression with post-operative radiotherapy (DADSPORT): A collaborative meta-analysis of aggregate data","volume":"33","author":"Burdett","year":"2022","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0036","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.009_bib0037","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13014-021-01811-8","article-title":"A survey among German-speaking radiation oncologists on PET-based radiotherapy of prostate cancer","volume":"16","author":"Vogel","year":"2021","journal-title":"Radiat Oncol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.009_bib0038","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","article-title":"68Ga-PSMA-PET\/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET\/CT","volume":"41","author":"Bluemel","year":"2016","journal-title":"Clin Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.009_bib0039","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","article-title":"Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET\/CT","volume":"44","author":"Schwenck","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2967\/jnumed.117.203257","article-title":"Comparison of (68)Ga-PSMA-11 and (18)F-Fluciclovine PET\/CT in a Case Series of 10 Patients with Prostate Cancer Recurrence","volume":"59","author":"Calais","year":"2018","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0041","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid \u2076\u2078Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0042","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive (68)Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.009_bib0043","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Afshar-Oromieh","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.009_bib0044","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid (6)(8)Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.009_bib0045","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.eururo.2024.01.012","article-title":"Impact of Prostate-specific Membrane Antigen Positron Emission Tomography\/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"issue":"10288","key":"10.1016\/j.semradonc.2025.04.009_bib0046","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.009_bib0047","doi-asserted-by":"crossref","first-page":"586","DOI":"10.2967\/jnumed.122.264832","article-title":"Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus (18)F-Fluciclovine PET\/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial","volume":"64","author":"Lawal","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.009_bib0048","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s40644-023-00570-x","article-title":"Influence of molecular imaging on patient selection for treatment intensification prior to salvage radiation therapy for prostate cancer: a post hoc analysis of the PROPS trial","volume":"23","author":"Tremblay","year":"2023","journal-title":"Cancer Imaging"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.009_bib0049","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0050","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year Freedom from Progression After (68)Ga-PSMA PET\/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial","volume":"61","author":"Emmett","year":"2020","journal-title":"J Nucl Med"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0051","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.009_bib0052","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.ijrobp.2022.12.038","article-title":"Genomic Classifiers in Personalized Prostate Cancer Radiation Therapy Approaches: A Systematic Review and Future Perspectives Based on International Consensus","volume":"116","author":"Spohn","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.semradonc.2025.04.009_bib0053","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","article-title":"Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG\/RTOG 9601 Randomized Clinical Trial","volume":"7","author":"Feng","year":"2021","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.009_bib0054","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.annonc.2022.05.007","article-title":"Validation of the Decipher genomic classifier in patients receiving salvage radiotherapy without hormone therapy after radical prostatectomy - an ancillary study of the SAKK 09\/10 randomized clinical trial","volume":"33","author":"Dal Pra","year":"2022","journal-title":"Ann Oncol"},{"issue":"5S","key":"10.1016\/j.semradonc.2025.04.009_bib0055","first-page":"e897","article-title":"PD42-11\u2003 Development and validation of a multimodal artificial intelligence (MMAI)-derived digital pathology-based biomarker predicting metastasis for radical prostatectomy patients with biochemical recurrence in NRG\/RTOG trials","volume":"211","author":"Morgan","year":"2024","journal-title":"Journal of Urology [Internet]"},{"issue":"16","key":"10.1016\/j.semradonc.2025.04.009_bib0056","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.009_bib0057","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.euo.2024.04.014","article-title":"Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial","volume":"8","author":"Ah-Thiane","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0058","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.euo.2020.01.005","article-title":"Phase II Trial of Enzalutamide and Androgen Deprivation Therapy with Salvage Radiation in Men with High-risk Prostate-specific Antigen Recurrent Prostate Cancer: The STREAM Trial","volume":"4","author":"Bitting","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"6_suppl","key":"10.1016\/j.semradonc.2025.04.009_bib0059","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2023.41.6_suppl.303","article-title":"FORMULA-509: A multicenter randomized trial of post-operative salvage radiotherapy (SRT) and 6 months of GnRH agonist with or without abiraterone acetate\/prednisone (AAP) and apalutamide (Apa) post-radical prostatectomy (RP)","volume":"41","author":"Nguyen","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.009_bib0060","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1200\/JCO.22.01662","article-title":"Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial","volume":"41","author":"Tran","year":"2023","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.semradonc.2025.04.009_bib0061","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2024.42.4_suppl.131","article-title":"Intensification of ADT with enzalutamide in high-risk patients with biochemical relapse following radical prostatectomy undergoing salvage radiation: Initial results from RTOG 3506 (STEEL)","volume":"42","author":"Posadas","year":"2024","journal-title":"Journal of Clinical Oncology"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000372?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000372?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:05:57Z","timestamp":1750791957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000372"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000372"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.009","relation":{},"ISSN":["1053-4296"],"issn-type":[{"value":"1053-4296","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative Radiation Therapy and Controversies Regarding Hormonal Therapy in the Management of Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}